Skip to main content
. 2018 Jan 11;9:131–140. doi: 10.1016/j.molmet.2018.01.005

Figure 2.

Figure 2

INT-767 reverses HFD-induced metabolic disorders via activation of TGR5 and/or FXR. Male WT mice, Tgr5−/− mice and Fxr−/− mice were fed a high fat diet (60% kcal from fat) for 12 weeks (n = 6–7 per group). By the end of week 12, mice were gavaged with either vehicle or INT-767 once a day for 10 days. (A) Body fat was measured by Echo-MRI before or after INT-767 treatment. (B) Plasma glucose. (C) Plasma TG. (D) Plasma cholesterol. (E) Hepatic TG. (F) Plasma ALT. (G) Hepatic de novo TG synthesis was analyzed by GC mass spectrometry. (H) Hepatic mRNA levels. (I) mRNA levels in brown adipose tissue (BAT). NS, not significant. *P < 0.05, **P < 0.01.